Neointima
Showing 1 - 25 of 93
Coronary Artery Disease, Restenoses, Coronary Trial in Munich (Drug eluting stent (DES), Drug coated ballloon (DCB))
Recruiting
- Coronary Artery Disease
- Restenoses, Coronary
- Drug eluting stent (DES)
- Drug coated ballloon (DCB)
-
Munich, GermanyDeutsches Herzzentrum München
Oct 12, 2022
Patients With Restenosis of Calcified Lesions
Recruiting
- Coronary Artery Calcification
- +3 more
- Coronary artery calcification lesions
-
Shenyang, Liaoning, ChinaShenyangNH
Jul 14, 2022
Coronary Artery Disease, Stable Angina Pectoris, Unstable Angina Pectoris Trial in BeiJing (BuMA Supreme™ stent, Xience V/Prime
Completed
- Coronary Artery Disease
- +2 more
- BuMA Supreme™ stent
- Xience V/Prime stent
-
BeiJing, Beijing, ChinaThe PLA General Hospital
Oct 11, 2021
Atherosclerosis, Neointima, Angina Trial in Seoul (Pitavastatin 1mg, Pitavastatin 4mg, Placebo)
Completed
- Atherosclerosis
- +2 more
- Pitavastatin 1mg
- +2 more
-
Seoul, Korea, Republic ofKorea University Anam Hospital
Nov 8, 2020
Coronary Heart Disease, Angioplasty, Balloon Trial in Xi'an (Drug-coated balloon, Drug-eluting stents)
Active, not recruiting
- Coronary Heart Disease
- Angioplasty, Balloon
- Drug-coated balloon
- Drug-eluting stents
-
Xi'an, Shannxi, ChinaLing Tao
Jun 29, 2023
Atherosclerosis, Diabetes, Restenosis Trial in Stockholm (Bydureon, Humulin kwickpen, Metformin)
Recruiting
- Atherosclerosis
- +2 more
- Bydureon
- +2 more
-
Stockholm, Other, SwedenDept of clinical science and education Karolinska Institutet Söd
Aug 31, 2021
In-stent Restenosis, Major Adverse Cardiovascular Events Trial in Beijing (PCSK9 inhibitor, Statin)
Recruiting
- In-stent Restenosis
- Major Adverse Cardiovascular Events
- PCSK9 inhibitor
- Statin
-
Beijing, Beijing, ChinaBeijing Anzhen Hospital
Jan 16, 2023
Associated With In-stent Restenosis After Percutaneous Coronary
Not yet recruiting
- In-stent Restenosis
- bone morphogenetic protein-2 (BMP-2)
- (no location specified)
Nov 20, 2023
Coronary Artery Disease Trial in Japan (Cilostazol eluting stent system (CES-1))
Active, not recruiting
- Coronary Artery Disease
- Cilostazol eluting stent system (CES-1)
-
Isehara, Kanagawa, Japan
- +5 more
Mar 28, 2022
De Novo Stenosis, Coronary Artery Disease, Percutaneous Coronary Intervention Trial in Xi'an (Lepu Paclitaxel coated balloon,
Recruiting
- De Novo Stenosis
- +2 more
- Lepu Paclitaxel coated balloon
- +4 more
-
Xi'an, Shannxi, ChinaLing Tao
Jul 20, 2022
Coronary Artery Disease Trial in Kunming (Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS), Abbott Vascular
Recruiting
- Coronary Artery Disease
- Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS)
- Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
-
Kunming, ChinaFuwai Yunnan Cardiovascular Hospital
Mar 16, 2022
Coronary Disease Trial in Beijing (Paclitaxel DCB, DES)
Completed
- Coronary Disease
- Paclitaxel DCB
- DES
-
Beijing, Beijing, ChinaBeijing Hospital
Mar 21, 2022
De Novo Stenosis, Coronary Artery Disease Trial in Xi'an (Swide Paclitaxel coated balloon, Firebird2 Sirolimus eluting stents,
Active, not recruiting
- De Novo Stenosis
- Coronary Artery Disease
- Swide Paclitaxel coated balloon
- +4 more
-
Xi'an, Shannxi, ChinaLing Tao
Jul 20, 2022
Neoatherosclerosis in ISR Patients Based on Artifical
Recruiting
- In-stent Restenosis
- +2 more
- no interventin
-
Beijing, ChinaThe General Hospital of PLA
Jan 13, 2021
Blood Endothelium Progenitor Cells and Dendritic Cells as
Completed
- Atherosclerosis
- Restenosis
-
Edegem, Antwerpen, BelgiumUniversitair Ziekenhuis Antwerpen
Nov 3, 2022
Renal Dialysis, Hemodynamics, Vascular Remodeling Trial in Leiden (PEG-liposomal prednisolone sodium phosphate, Placebo)
Terminated
- Renal Dialysis
- +3 more
- PEG-liposomal prednisolone sodium phosphate
- Placebo
-
Leiden, Zuid Holland, NetherlandsLeiden University Medical Center
Sep 17, 2018
Symptomatic Carotid Stenosis, Hypercholesterolemia, Indication for Carotid Endarterectomy Trial in Chieti, Padova, Treviso
Completed
- Symptomatic Carotid Stenosis
- +2 more
- Atorvastatin - Cholestyramine - Sitosterol
-
Chieti, Italy
- +2 more
Apr 28, 2021
Apoptosis Proteins and Endothelial Dysfunction in
Active, not recruiting
- Atherosclerosis
- Endothelial Dysfunction
- Bypass surgery
- +6 more
-
Ryazan', Russian FederationRyazan State Medical University
Sep 22, 2021
Percutaneous Coronary Intervention, Myocardial Revascularization, Tomography, Optical Coherence Trial in Genk, Leuven, Rotterdam
Recruiting
- Percutaneous Coronary Intervention
- +2 more
- Fantom Encore Bioresorbable scaffold implantation
-
Genk, Belgium
- +2 more
Oct 12, 2020
AR, IGF-IR, IR and Peripheral Artery Disease
Recruiting
- Androgen Receptor Abnormal
- +2 more
- arterial reconstructive open surgery
-
Catanzaro, ItalyUniversity Magna Graecia of Catanzaro
Jan 12, 2021
Coronary Disease Trial in Austria, Germany, Israel (2% rapamycin-eluting YUKONdes PEARL-stent, 1% rapamycin-eluting YUKONdes
Terminated
- Coronary Disease
- 2% rapamycin-eluting YUKONdes PEARL-stent
- +2 more
-
Salzburg, Austria
- +9 more
Oct 6, 2020
STEMI Trial in Brussels (the ABSORB:bioresorbable vascular scaffold, O.M.T)
Completed
- STEMI
- the ABSORB:bioresorbable vascular scaffold
- O.M.T
-
Brussels, BelgiumStLuc
May 4, 2020
Stent Restenosis, Intimal Hyperplasia Trial in Vienna (Pulsar Stent, LifeStent Flexstar Vascular Stent)
Unknown status
- Stent Restenosis
- Intimal Hyperplasia
- Pulsar Stent
- LifeStent Flexstar Vascular Stent
-
Vienna, AustriaMedical University of Vienna
Feb 19, 2020
Neurofibromatosis Type 1, Plexiform Neurofibroma Trial in United States (Binimetinib)
Active, not recruiting
- Neurofibromatosis Type 1
- Plexiform Neurofibroma
-
Birmingham, Alabama
- +21 more
Dec 4, 2021
GVHD Trial in Hackensack (Telmisartan)
Active, not recruiting
- GVHD
-
Hackensack, New JerseyHackensack University Medical Center
Sep 2, 2022